Investment Thesis
Alumis is a pre-revenue pharmaceutical company with severe cash burn and unsustainable operating losses. Despite holding adequate cash reserves ($65.3M), the company is burning approximately $298M annually in free cash flow, indicating a runway of less than 3 quarters at current burn rates. Without demonstrated revenue generation or clear path to profitability, the fundamental financial position is critically deteriorating.
ALMS Strengths
- Strong liquidity position with $65.3M cash and 6.01x current ratio providing near-term operational flexibility
- Low leverage with minimal debt obligations reducing immediate refinancing risk
- Substantial asset base of $488M suggests intellectual property or development assets in pharmaceutical pipeline
ALMS Risks
- Catastrophic cash burn of -$298.3M in free cash flow annually will deplete reserves within 2-3 quarters at current rates
- Minimal revenue of $22.1M against -$357.4M operating loss indicates no viable commercial operations or product market fit
- Negative net margin of -679.9% and -$150.4M net loss demonstrate inability to control costs relative to revenue
- Early-stage pharma company with unproven drug development success - typical attrition rates are extremely high
- Operating losses and negative cash flow unsustainable without major capital raise, partnership, or acquisition
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway - critical for survival timeline
- Revenue growth trajectory - any meaningful revenue would require successful clinical trials and FDA approvals
- Operating expense reduction initiatives and burn rate improvement
- Financing activities and capital raise announcements - likely necessity given cash depletion timeline
- Pipeline clinical trial progress and regulatory milestones for lead candidates
ALMS Financial Metrics
ALMS Profitability Ratios
ALMS Balance Sheet & Liquidity
ALMS 5-Year Financial Trend
5-Year Trend Summary: ALUMIS INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-72.08 indicates the company is currently unprofitable.
ALMS Growth Metrics (YoY)
ALMS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1M | -$49.8M | $-1.06 |
| Q2 2025 | $2.7M | -$39.6M | $-0.61 |
| Q1 2025 | $17.4M | -$49.8M | $-1.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ALMS Capital Allocation
ALMS SEC Filings
Access official SEC EDGAR filings for ALUMIS INC. (CIK: 0001847367)